



# NCG-KCDO EMR Requirement (NER)Preventive Oncology Module (Version 1.0)

(Version 1.0)





### **FOREWORD**

The National Cancer Grid (NCG) Electronic Medical Records (EMR) initiative has been well received by the NCG Hospitals and our community of healthcare professionals and stakeholders. The enthusiasm and support we have garnered for this initiative reflect a shared commitment to advancing cancer care through technology and collaboration.

As part of our ongoing efforts to enhance the EMR initiative, the Preventive Oncology template has been developed. This template aims to streamline the documentation of cancer prevention measures, ensuring comprehensive patient care and facilitating early detection and intervention. It enhances data accuracy and supports proactive healthcare management.

We share the pre-final version of the Preventive Oncology template and welcome feedback, suggestions and guidance from the healthcare professionals involved in treating patients with cancer, healthcare technology companies and providers. Your inputs will help develop EMRs with strong cancer care workflows which in turn will ensure better care, outcomes and value-based care for patients with Cancer across India.

**Dr C.S. Pramesh**Convener, National Cancer Grid
August 2024





### Contents

1. NCG EMR INITIATIVE OVERVIEW	4
2. Preventive Oncology Template Overview	4
3. Preventive Oncology Form	5
4. Appendices	12
Appendix 1- Glossary of terms	12
Appendix 2- NFR Document	





### 1. NCG EMR INITIATIVE OVERVIEW

The National Cancer Grid Koita Centre for Digital Oncology (NCG KCDO) launched an initiative to empanel Electronic Medical Records (EMR) vendors and help develop high quality EMR solutions that are appropriate for use in hospitals providing cancer care. This marks a significant milestone in the ongoing efforts to promote digital health and enhance cancer care across the country. Launched with the aim of standardizing and improving clinical practices in oncology, it is a collaborative approach involving leading healthcare institutions, clinicians, and technology partners.

In March 2023, NCG KCDO released the NCG EMR Requirements (NER) – a comprehensive set of EMR requirements needed for effective management of patients with cancer. The NER is a blueprint for the development and implementation of robust EMR systems which will serve general hospitals well, but are also tailored specifically for oncology practices. The NER document is a result of intense deliberations over several months between healthcare professionals involved in cancer care and technology experts, and is available as a digital public good at NCG-KCDO EMR Initiative.

To further support the development of the empanelled EMR systems, the NCG is developing detailed requirements and features in specific areas of oncology including radiotherapy, chemotherapy, surgical, multi-disciplinary tumour board, palliative care and preventive oncology. This document details the preventive oncology requirements and features, based on best practices developed at several leading NCG centres.

## 2. Preventive Oncology Template Overview

Building on the features outlined in the NER (NCG EMR Requirement), the Preventive Oncology template is designed to streamline and optimize the preventive oncology screening documentation for early identification and treatment initiation.

Key features of the Preventive Oncology Template include:

- **2.1 Data Elements Standardization:** The template ensures the standardized collection and storage of essential data elements related to preventive oncology, including patient demographics, clinical history, screening results, and follow-up plans.
- **2.2 Screening and Documentation:** The template provides robust functionality for documenting routine cancer screenings, capturing patient symptoms, and recording the duration of symptoms.
- **2.3 Comorbidity and History Recording:** It includes detailed sections for capturing patient comorbidities, menstrual history, obstetric history, contraceptive history, hormone replacement therapy history, family history of cancer, and lifestyle habits.





**2.4 Examination and Follow-Up:** The template supports comprehensive documentation of general examinations, breast and cervical examinations (for females), and follow-up plans for patients completing preventive oncology screenings.

# 3. Preventive Oncology Form

	Preventive Oncology				
SNo	Data Elements	Clinician's Response	Remarks for Vendors		
Α	Case Number				
В	Visit No		Auto populate as per case no		
С	Name		Auto populate as per case no		
D	Age/Sex		Auto populate as per case no		
Е	Name of the doctor				
1	Registration				
Α	Routine Screening	☐ Yes ☐ No			
В	Asymptomatic	☐ Yes ☐ No	If the response to 1B is 'yes', 1C should be disabled.		
С	Symptoms	<ul><li>☐ Others</li><li>☐ Swelling</li><li>☐ Functional Difficulty</li><li>☐ Deformity</li><li>☐ Pain</li></ul>			
D	Duration of symptoms- Since	☐ Years ☐ Months ☐ Weeks ☐ Days	Number		
2	History				
А	Comorbidities	<ul><li>☐ Yes</li><li>☐ No</li><li>☐ Unknown</li></ul>	Multiple choice possible. If the response to 2A is yes, following table to be enabled.		
Name		Age at onset of comorbidities	Duration		
☐ Re	enal disease		Years		





☐ He ☐ He ☐ Di ☐ Ca ☐ BI ☐ As	pertension epatitis eart disease abetes		☐Months ☐ Weeks ☐ Days
В	Remarks		Free text box
Б	Remarks		Thee text box
3	Menstrual History		To be enabled for females only
	Triciloti dali Triciloti y		To be enabled for fermanes emy
Α	Menstrual history	☐ Yes ☐ No ☐ Unknown	If the response to 3A is No, 3B-3F to be disabled
В	Menopause Status	<ul><li>□ Pre Menarchal</li><li>□ Pre-menopausal</li><li>□ Peri Menopausal</li><li>□ Post Menopausal</li></ul>	
С	LMP Date	·	Calendar view
D	Marital Status	<ul><li>☐ Married</li><li>☐ Unmarried</li><li>☐ Separated</li><li>☐ Divorced</li></ul>	
Е	Age at Marriage (In years)		
F	Hysterectomy done	☐ Yes ☐ No	
4	Obstetric History		To be enabled for females only
		_	
Α	Obstetric history	☐ Yes ☐ No ☐ Unknown	If the response to 4A is No, 4B-4K to be disabled
В	Gravida		
С	Para		
D	Abortion		In Number
E	Living Children		In Number
F	Normal Delivery		In Number
G	Caesarean Section		In Number





7	Family History		
7	Family History		
E	Remarks		
D	Route of administration Remarks		
С	From Date	☐ SERMs	
В	Type of therapy	<ul> <li>□ Oestrogen only</li> <li>□ Oestrogen-Progestogen</li> <li>Sequential</li> <li>□ Oestrogen-Progestogen</li> <li>Continuous Combined</li> <li>□ Tibolone</li> </ul>	
Α	Hormone Replacement Therapy History	☐ Yes ☐ No ☐ Unknown	If the response to 6A is No, row 6B-6D to be disabled
	.,		
6	Hormone Replacement Therapy History		To be enabled for females only
D	Remarks		
С	Duration		
В	Contraceptives  Contraceptive type	<ul> <li>No</li> <li>Unknown</li> <li>Oral Pills</li> <li>Tubal ligation</li> <li>Natural method</li> <li>Barrier</li> <li>Sterilization</li> <li>I.U.D</li> <li>Injectables</li> <li>Others,</li> </ul>	and 5C to be disabled
	Calandia	☐ Yes	If the response to 5A is No, row 5B
5	Contraceptive History		To be enabled for females only
_			
К	Duration of breastfeeding (In months)		Row 4K to be enabled only if the response to 4J is 'Yes'.
J	Have you ever breastfed your child?	☐ Yes ☐ No	
ı	No of Still Births		In Number
Н	No of Dead children		In Number





	Α	Family history of cancer		☐ Yes ☐ No ☐ Unk	nown			response to 7A be disabled	is No, row 7B-	
	В	Relatio	n with the pation	ent						
	С	Cancer	Site							
	D	Laterali	ity							
	Е	Age at ( (years)	onset of diseas	e				In Nur	mber	
	F	Duratio	n (In months/Y	'ears)				In Nur	mber	
	G	Status				ase free ative Care		In Nur	nber	
	8	Substa	nce Abuse Hist	ory						
	A	Substar	nce Abuse Histo	ory	☐ Yes ☐ No ☐ Unk	nown			response to 8A be disabled	is No, row 7B-
	В	Habits						Multip	ole choice poss	ible
	☐ Be leave ☐ Be Nut ☐ Cig ☐ Gu ☐ M. ☐ Pa Masa ☐ Sn	cohol eedi etal s etel garatte utka asheri in	Quantity	Age we the he starte years	iabit ed (In	Duration  Days Days Meeks Month Myears	Has th patien the ha	t quit bit	If yes, what was the age of the patient	Duration since the patient has quit  Days Meeks Month Years
	Chew	ring :hers								
L	0	.11613								
	С	Remark	KS					Open	text box	





9	History of previous Cancer			
Α	History of previous cancer	☐ Yes ☐ No ☐ Unknown	If the response to 9A is No, row 9B- and 9C to be disabled	
В	Diagnosis			
С	Type of treatment	<ul> <li>□ Bone Marrow Transplant</li> <li>□ Stenting</li> <li>□ Hormone Therapy</li> <li>□ Symptomatic</li> <li>□ Radiology Intervention</li> <li>□ Endoscopy Intervention</li> <li>□ Chemotherapy</li> <li>□ Radiology</li> <li>□ Surgery</li> </ul>		
10	General Examination			
Α	Height/Length (in cm)			
В	Weight (kg)			
С	BMI			
D	BSA (sq m)			
E	General Examination	<ul> <li>□ Oedema</li> <li>□ Cyanosis</li> <li>□ Clubbing</li> <li>□ Purpura</li> <li>□ Obesity</li> <li>□ Icterus</li> <li>□ Pallor</li> </ul>		
F	Nutrition		Free text box	
G	Hydration		Free text box	
Н	Mouth and Oral Cavity Examination Findings- Lips/Tongue/ Teeth/Gums/ Buccal Mucosa			
I	Breast Examination Findings	(for Females only)		
Signs	of Breast surgery	Yes No Others	Right  Yes  No Others	
		Abnormal	☐ Abnormal	





Palpation  Other significant findings  J Cervical Examination Findings (To be enabled for females only)    VIA			Normal	☐ Normal	
J Cervical Examination Findings (To be enabled for females only)    VIA	Palpation				
J Cervical Examination Findings (To be enabled for females only)    VIA					
J Cervical Examination Findings (To be enabled for females only)    VIA	Othe	r significant findings			
i VIA   Positive   Negative   Inconclusive   Positive   Negative   Inconclusive   Positive   Positi	Othe	i significant manigs			
i VIA   Positive   Negative   Inconclusive   Positive   Negative   Inconclusive   Positive   Positi					
ii VIA   Negative   Inconclusive    ii VILLI	J	Cervical Examination Finding	gs (To be enabled for females o	nly)	
ii VIA   Negative   Inconclusive    ii VILLI					
Inconclusive   Inconclusive					
ii VILLI    Normal     Invasive Cancer   CiN 3   CiN 2   CiN 1   HPV Changes   Polyp   Cervicitis   Erosion   Atrophy   Others    Remarks   Free text box   Multiple Choice Possible	i	VIA	=		
Normal   Invasive Cancer   CIN 3   CIN 2   CIN 1   HPV Changes   Polyp   Cervicitis   Erosion   Atrophy   Others		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	☐ Inconclusive		
Invasive Cancer   CIN 3   CIN 2   CIN 1   HPV Changes   Choose one   Polyp   Cervicitis   Erosion   Atrophy   Others   Multiple Choice Possible      I	II	VILLI	Normal		
CIN 3					
CIN 2					
Impression					
Polyp   Cervicitis   Erosion   Atrophy   Others    L Remarks   Free text box   Multiple Choice Possible      Oral			☐ CIN I		
□ Cervicitis □ Erosion   □ Atrophy □ Others   I Remarks Free text box   M Investigations Advised Multiple Choice Possible      Oral Brush Cytology   Oral Punch Biopsy   USG Neck   Others	K	Impression	_	Choose one	
□ Erosion □ Atrophy   □ Others Free text box   M Investigations Advised Multiple Choice Possible      Oral Brush Cytology   □ Oral Punch Biopsy □ USG Neck   □ Others      Bilateral Mammography   □ USG B/L Breast & Axilla   □ Others      PAP Smear   □ HPV DNA   □ Cervical □ Cervical Punch Biopsy   □ Endocervical Curetage   □ Others					
□ Atrophy □ Others   L Remarks Free text box   M Investigations Advised Multiple Choice Possible      Oral Brush Cytology   Oral Punch Biopsy   USG Neck   Others     USG Neck   Others     USG B/L Breast & Axilla   Others     USG B/L Breast & Axilla   Others     PAP Smear   HPV DNA   Cervical Punch Biopsy   Endocervical Curetage   Others     Others   Sr. PSA   USG Pelvis					
L Remarks Free text box   M Investigations Advised Multiple Choice Possible      Oral Brush Cytology					
L Remarks Investigations Advised  Multiple Choice Possible  Oral Brush Cytology Oral Punch Biopsy USG Neck Others  Bilateral Mammography USG B/L Breast & Axilla Others  PAP Smear HPV DNA Cervical Pendocervical Curetage Others  Sr. PSA iv Prostate  Free text box Multiple Choice Possible					
i Oral Brush Cytology	L	Remarks		Free text box	
i Oral Brush Cytology	М	Investigations Advised		Multiple Choice Possible	
ii Oral □ Oral Punch Biopsy □ USG Neck □ Others  Bilateral Mammography □ USG B/L Breast & Axilla □ Others  □ PAP Smear □ HPV DNA □ Cervical Punch Biopsy □ Endocervical Curetage □ Others  iv Prostate □ Sr. PSA □ USG Pelvis					
USG Neck ☐ Others  □ Bilateral Mammography ☐ USG B/L Breast & Axilla ☐ Others  □ PAP Smear ☐ HPV DNA ☐ Cervical Punch Biopsy ☐ Endocervical Curetage ☐ Others  □ Sr. PSA ☐ USG Pelvis			☐ Oral Brush Cytology		
USG Neck ☐ Others  ☐ Bilateral Mammography ☐ USG B/L Breast & Axilla ☐ Others ☐ PAP Smear ☐ HPV DNA ☐ Cervical Punch Biopsy ☐ Endocervical Curetage ☐ Others ☐ USG Pelvis	i	Oral			
Bilateral Mammography   USG B/L Breast & Axilla   Others   PAP Smear   HPV DNA   Cervical Punch Biopsy   Endocervical Curetage   Others   Others   USG Pelvis	'	Ordi			
ii Breast USG B/L Breast & Axilla Others  PAP Smear HPV DNA Cervical Cervical Punch Biopsy Endocervical Curetage Others  iv Prostate Sr. PSA USG Pelvis					
□ Others □ PAP Smear □ HPV DNA □ Cervical □ Cervical Punch Biopsy □ Endocervical Curetage □ Others □ Sr. PSA □ USG Pelvis	ii	Broact			
□ PAP Smear □ HPV DNA □ Cervical Punch Biopsy □ Endocervical Curetage □ Others  iv Prostate □ USG Pelvis	"	bieast			
iii Cervical ☐ HPV DNA ☐ Cervical Punch Biopsy ☐ Endocervical Curetage ☐ Others  iv Prostate ☐ USG Pelvis					
☐ Endocervical Curetage ☐ Others  ☐ Sr. PSA ☐ USG Pelvis			☐ HPV DNA		
USG Pelvis  □ Others □ Sr. PSA □ USG Pelvis	iii	Cervical	☐ Cervical Punch Biopsy		
iv Prostate ☐ Sr. PSA ☐ USG Pelvis					
iv Prostate   USG Pelvis					
	į.,	Prostato			
	IV	riustate	☐ Others		





V	Abdomen	☐ USG Abdomen ☐ USG Pelvis ☐ Others	
vi	Thorax	☐ Chest X-Ray ☐ CT Thorax ☐ Others	
vii	USG - Other Sites		
viii	Tumor Markers	☐ CA 125 ☐ CA 19.9 ☐ CEA ☐ AFP ☐ Others	
ix	Blood Investigations	☐ CBC ☐ Routine Biochemistry  • RFT • LFT • Sr Electrolytes ☐ FBS ☐ PPBS ☐ HbA1c ☐ Lipid Profile ☐ Others	
N	Follow up Screening Advised		
i	Oral	<ul><li>☐ After 3 months</li><li>☐ After 6 months</li><li>☐ After 1 year</li></ul>	
ii	Breast	☐ After 3 months ☐ After 6 months ☐ After 1 year ☐ After 2 years	
iii	Cervical	<ul><li>☐ After 3 months</li><li>☐ After 6 months</li><li>☐ After 1 year</li><li>☐ After 2 years</li></ul>	
0	Refer to other departments		
Р	Refer Outside		
		End	





# 4. Appendices

# Appendix 1- Glossary of terms

	Abbreviations
NCG	National Cancer Grid
EMR	Electronic Medical Record
NER	NCG EMR Requirements
LEAP	Leading EMR Adoption Program
CIN	Cervical Intraepithelial Neoplasia
BMI	Body Mass Index
IUD	Intra Uterine Device
LFT	Liver Function Test
RFT	Renal Function Test
FBS	Fasting Blood Sugar
PPBS	Post-Prandial Blood Sugar
AFP	Alpha- Fetoprotein
CEA	Carcinoembryonic Antigen

### Appendix 2- NER Document

1. ncg-emr-requirements-ner.pdf (kcdo.in)